SENSE (Subcutaneous and Epidural Neuromodulation System Evaluation) Study
TerminatedNot applicableNCT01990287
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of the study is to demonstrate safety and efficacy of spinal cord stimulation with peripheral nerve field stimulation for the treatment of chronic low back and leg pain.
Study details
- Official title
- SENSE (Subcutaneous and Epidural Neuromodulation System Evaluation)Study for the Treatment of Chronic Low Back and Leg Pain
- Conditions
- Failed Back Surgery Syndrome
- Post-Laminectomy Syndrome
- Low Back Pain
- Interventions
- Device: SCS and PNfS
- Device: SCS Alone
- Sponsor
- Abbott Medical Devices
- Start date
- 2013-11
- Primary completion
- 2016-02
- Sex
- All
- Age range
- from 22 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 28
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Key Inclusion Criteria: * Subject is 22 years of age or older * Subject has chronic low back and leg pain secondary to Failed Back Surgery Syndrome (FBSS) * Subject has an average score of 6 or higher for average daily overall pain on the Numerical Rating Scale (NRS) based on the 7 day pain diary * Subject has attempted "best" medical therapy and has tried and failed at least three documented medically supervised treatments (including, but not limited to physical therapy, acupuncture, etc.) and has failed medication treatment from at least two different classes * Subject's pain-related medication regimen is stable 4 weeks prior to the baseline evaluation * Subject agrees not to add or increase pain-related medication throughout the 12 week randomized evaluation phase of the study (starting at activation) Key Exclusion Criteria: * Subject currently participating in a clinical investigation that includes an active treatment arm * Subject has been implanted with a previous neuromodulation system (PNfS, SCS-PNfS or SCS) or participated in a trial for a neuromodulation system * Subject's overall Beck Depression Inventory II Score is \> 24 or has a score of 3 on question 9 relating to suicidal thoughts or wishes at the baseline visit * Subject with an infusion pump or any implantable neurostimulator device * Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor) * Subject has an existing medical condition that is likely to require the use of diathermy in the future * Subject has peripheral vascular disease * Subject is immunocompromised * Subject has documented history of allergic response to titanium or silicone * Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection * Female candidates of child bearing potential that are pregnant (confirmed by positive pregnancy test)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01990287